Announcement on Obtaining the Notice of Approval for Drug Clinical Trial of Innovative Drug HSK47388 Tablets (I) for New Indications

Haisco Pharmaceutical Group Co., Ltd.·August 18, 2026·2 pages

✨ AI Summary

Hesk Pharma announced it received a Notice of Approval for Drug Clinical Trial from the NMPA for its innovative drug HSK47388 Tablets (I) for a new indication. This approval allows the company to proceed with clinical trials for psoriatic arthritis. The drug is an oral, potent, and highly selective medication. This development is expected to enrich the company's product pipeline and offer better treatment options for autoimmune diseases.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002653

Stock Abbreviation: Hesk Pharma

Announcement No.: 2026-092

Hesk Pharma Group Co., Ltd.

Announcement on Obtaining the Notice of Approval for Drug Clinical Trial of Innovative Drug HSK47388 Tablets (I) for New Indications

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or material omissions.

Hesk Pharma Group Co., Ltd. (hereinafter referred to as the "Company") recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, and the relevant situation is hereby announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.